• Genmab announced updated Phase 2 results showing tumor responses to investigational petosemtamab with chemotherapy in first- and second-line metastatic colorectal cancer.
• Longer follow-up confirmed most previously unconfirmed responses, supporting the durability of treatment effects.
• Findings were presented at the European Society for Medical Oncology Congress 2026 in Madrid.
• The results support ongoing global Phase 3 colorectal cancer trials, which are actively enrolling patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 202610250700BIZWIRE_USPR_____20261023_BW396881) on October 25, 2026, and is solely responsible for the information contained therein.